<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:03:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10106049" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10106049</identifier>
        <datestamp>2023-04-17</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10106049</article-id>
              <article-id pub-id-type="pmcid">PMC10106049</article-id>
              <article-id pub-id-type="pmc-uid">10106049</article-id>
              <article-id pub-id-type="pmid">37055198</article-id>
              <article-id pub-id-type="pmid">37055198</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2023-073400</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2023-073400</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Paediatrics</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1719</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Providing Oxygen during Intubation in the NICU Trial (POINT): study protocol for a randomised controlled trial in the neonatal intensive care unit in the USA</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-106016775" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0723-6898</contrib-id>
                  <name>
                    <surname>Herrick</surname>
                    <given-names>Heidi M</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-106018967" contrib-type="author">
                  <name>
                    <surname>O'Reilly</surname>
                    <given-names>Mackenzie</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-106018974" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Sura</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-106018985" contrib-type="author">
                  <name>
                    <surname>Wildenhain</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-106019005" contrib-type="author">
                  <name>
                    <surname>Napolitano</surname>
                    <given-names>Natalie</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-106019091" contrib-type="author">
                  <name>
                    <surname>Shults</surname>
                    <given-names>Justine</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-106019254" contrib-type="author">
                  <name>
                    <surname>Nishisaki</surname>
                    <given-names>Akira</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-106019270" contrib-type="author">
                  <name>
                    <surname>Foglia</surname>
                    <given-names>Elizabeth E</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <aff id="aff1"><label>1</label><institution content-type="department">Pediatrics, Division of Neonatology</institution>, <institution specific-use="Ringgold_6567">The Children's Hospital of Philadelphia</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff2"><label>2</label><institution content-type="department">Pediatrics</institution>, <institution specific-use="Ringgold_14640">University of Pennsylvania Perelman School of Medicine</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff3"><label>3</label><institution content-type="department">Respiratory Therapy</institution>, <institution specific-use="Ringgold_6567">The Children's Hospital of Philadelphia</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff4"><label>4</label><institution content-type="department">Pediatrics</institution>, <institution specific-use="Ringgold_6567">The Children's Hospital of Philadelphia</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff5"><label>5</label><institution content-type="department">Department of Biostatistics, Epidemiology, and Informatics, Division of Biostatistics</institution>, <institution specific-use="Ringgold_14640">University of Pennsylvania Perelman School of Medicine</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff6"><label>6</label><institution content-type="department">Anesthesiology and Critical Care Medicine</institution>, <institution specific-use="Ringgold_6567">The Children's Hospital of Philadelphia</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
                <aff id="aff7"><label>7</label><institution content-type="department">Anesthesiology and Critical Care Medicine</institution>, <institution specific-use="Ringgold_14640">University of Pennsylvania Perelman School of Medicine</institution>, <addr-line content-type="city">Philadelphia</addr-line>, <addr-line content-type="state">Pennsylvania</addr-line>, <country>USA</country></aff>
              </contrib-group>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Heidi M Herrick; <email>herrickh@chop.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>4</issue>
              <elocation-id>e073400</elocation-id>
              <history>
                <date date-type="received">
                  <day>06</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>28</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-04-13">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2023-073400.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2023-073400.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2023-073400.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Nearly half of neonatal intubations are complicated by severe desaturation (≥20% decline in pulse oximetry saturation (SpO<sub>2</sub>)). Apnoeic oxygenation prevents or delays desaturation during intubation in adults and older children. Emerging data show mixed results for apnoeic oxygenation using high-flow nasal cannula (NC) during neonatal intubation. The study objective is to determine among infants ≥28 weeks’ corrected gestational age (cGA) who undergo intubation in the neonatal intensive care unit (NICU) whether apnoeic oxygenation with a regular low-flow NC, compared with standard of care (no additional respiratory support), reduces the magnitude of SpO<sub>2</sub> decline during intubation.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>This is a multicentre, prospective, unblinded, pilot randomised controlled trial in infants ≥28 weeks’ cGA who undergo premedicated (including paralytic) intubation in the NICU. The trial will recruit 120 infants, 10 in the run-in phase and 110 in the randomisation phase, at two tertiary care hospitals. Parental consent will be obtained for eligible patients prior to intubation. Patients will be randomised to 6 L NC 100% oxygen versus standard of care (no respiratory support) at time of intubation. The primary outcome is magnitude of oxygen desaturation during intubation. Secondary outcomes include additional efficacy, safety and feasibility outcomes. Ascertainment of the primary outcome is performed blinded to intervention arm. Intention-to-treat analyses will be conducted to compare outcomes between treatment arms. Two planned subgroup analyses will explore the influence of first provider intubation competence and patients’ baseline lung disease using pre-intubation respiratory support as a proxy.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The Institutional Review Boards at the Children’s Hospital of Philadelphia and the University of Pennsylvania have approved the study. Upon completion of the trial, we intend to submit our primary results to a peer review forum after which we plan to publish our results in a peer-reviewed paediatric journal.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p>ClinicalTrials.gov Registry (<ext-link xlink:href="NCT05451953" ext-link-type="uri">NCT05451953</ext-link>).</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Neonatal intensive &amp; critical care</kwd>
                <kwd>NEONATOLOGY</kwd>
                <kwd>INTENSIVE &amp; CRITICAL CARE</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000133</institution-id>
                      <institution>Agency for Healthcare Research and Quality</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K08HS029029</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
                      <institution>National Institutes of Health</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R21HD103927</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This study uses nasal cannula to deliver apnoeic oxygenation, which is less expensive and easier to scale than high-flow nasal cannula devices used in other trials.</p>
                </list-item>
                <list-item>
                  <p>Inclusion criteria stipulate paralytic premedication which (1) increases intubation safety outcomes and (2) allows the study of only patients with apnoea versus other studies which included patients without apnoea.</p>
                </list-item>
                <list-item>
                  <p>This study employs a run-in phase where the first five patients at each site will receive apnoeic oxygenation enabling optimisation of bedside workflow prior to randomisation phase.</p>
                </list-item>
                <list-item>
                  <p>This pilot randomised controlled study has a relatively small sample size of 110 randomised patients.</p>
                </list-item>
                <list-item>
                  <p>Prospective consent approach will likely require many patients to be consented who are not ultimately enrolled in the trial.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Tracheal intubation is a common, life-saving, high-risk procedure for critically ill infants. Adverse events occur in 18% of tracheal intubations performed in the neonatal intensive care unit (NICU) setting, and almost half (48%) of NICU intubations are complicated by severe oxygen desaturation (≥20% decline in pulse oximetry saturation (SpO<sub>2</sub>)).<xref rid="R1" ref-type="bibr">1</xref> Among extremely preterm infants, severe desaturation events are now recognised as an important contributor to neonatal morbidity and impaired neurodevelopmental outcomes at 18-month follow-up.<xref rid="R2" ref-type="bibr">2–4</xref> Modifiable factors such as video laryngoscope and paralytic premedication are associated with lower rates of adverse events during neonatal intubation, but these practices do not prevent severe oxygen desaturation during intubation in NICU patients.<xref rid="R1" ref-type="bibr">1</xref></p>
              <p>Typical practice during intubation in the NICU setting is to remove respiratory support during laryngoscopy and intubation attempts. Patients are often apnoeic during this period due to premedication administration, a practice that is recommended by the American Academy of Pediatrics.<xref rid="R5" ref-type="bibr">5</xref> Apnoeic oxygenation is a strategy in which free-flowing oxygen is provided via nasal cannula (NC) during laryngoscopy and tracheal intubation. Apnoeic oxygenation has been demonstrated to prevent or delay oxygen desaturation during intubation in adults and older children.<xref rid="R6" ref-type="bibr">6–9</xref> Apnoeic oxygenation is now a clinical standard or quality improvement intervention in many paediatric acute care settings.<xref rid="R10" ref-type="bibr">10–13</xref></p>
              <p>Emerging data demonstrate mixed results for the use of apnoeic oxygenation among neonates.<xref rid="R14" ref-type="bibr">14 15</xref> One trial demonstrated a significant improvement in the composite outcome of intubation success without physiological deterioration. However, 26% of intubations in the trial were performed without premedication, and thus the neonates were not apnoeic during the intubation.<xref rid="R15" ref-type="bibr">15</xref> The second trial demonstrated no difference in the primary outcome of duration of oxygen desaturation.<xref rid="R14" ref-type="bibr">14</xref> Additionally, both studies used high-flow NC to provide apnoeic oxygenation which costs more and requires additional time and resources to set up compared with regular low-flow NC.<xref rid="R14" ref-type="bibr">14 15</xref> We designed this study to test the efficacy, feasibility and safety of apnoeic oxygenation delivered via NC among neonates with apnoea during tracheal intubation in the NICU.</p>
              <sec id="s1-1">
                <title>Aim</title>
                <p>The study objective is to determine among infants ≥28 weeks’ corrected gestational age (cGA) who undergo intubation in the NICU, whether apnoeic oxygenation with NC, compared with standard of care (no additional respiratory support), reduces the magnitude of SpO<sub>2</sub> decline during intubation. Secondary objectives include determining whether apnoeic oxygenation is safe and feasible to perform among NICU patients.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <p>This is a multicentre, prospective, unblinded, pilot randomised controlled trial in infants ≥28 weeks’ cGA who undergo intubation in the NICU.</p>
              <sec id="s2-1">
                <title>Population</title>
                <p>Patients will be recruited from two tertiary care delivery hospitals located in the USA. One site is a 100-bed level four NICU with 1300 admissions per year. The second site is a 40-bed level three NICU with over 700 admissions per year.</p>
              </sec>
              <sec id="s2-2">
                <title>Inclusion criteria</title>
                <p>Inclusion criteria are as follows:</p>
                <list list-type="order">
                  <list-item>
                    <p>Infants ≥28 weeks’ cGA.</p>
                  </list-item>
                  <list-item>
                    <p>Undergoing intubation in the NICU.</p>
                  </list-item>
                  <list-item>
                    <p>Premedication (including paralytic) administered for intubation.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-3">
                <title>Exclusion criteria</title>
                <p>Exclusion criteria are as follows:</p>
                <list list-type="order">
                  <list-item>
                    <p>Critical airway or airway anomaly.</p>
                  </list-item>
                  <list-item>
                    <p>Unstable haemodynamics (ie, active resuscitation).</p>
                  </list-item>
                  <list-item>
                    <p>Unable to achieve SpO<sub>2</sub> ≥90% prior to first intubation attempt.</p>
                  </list-item>
                  <list-item>
                    <p>Intubation performed by non-NICU provider (ie, anaesthesiology or otolaryngologist).</p>
                  </list-item>
                  <list-item>
                    <p>Cyanotic heart disease.</p>
                  </list-item>
                  <list-item>
                    <p>Unrepaired congenital diaphragmatic hernia.</p>
                  </list-item>
                  <list-item>
                    <p>Tracheal oesophageal fistula within 2 weeks of repair.</p>
                  </list-item>
                  <list-item>
                    <p>Tracheostomy.</p>
                  </list-item>
                  <list-item>
                    <p>Previous enrolment in the trial.</p>
                  </list-item>
                  <list-item>
                    <p>Nasal intubation.</p>
                  </list-item>
                  <list-item>
                    <p>Person with COVID-19 under investigation or COVID-19 positive.</p>
                  </list-item>
                  <list-item>
                    <p>Receiving extracorporeal membrane oxygenation support.</p>
                  </list-item>
                  <list-item>
                    <p>Conjoined twins.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-4">
                <title>Screening</title>
                <p>Potentially eligible patients will be screened daily by a study team member using data extracted from the electronic medical record (EMR) and automatically imported into the Research Electronic Data Capture (REDCap) tool. REDCap is a secure, Health Insurance Portability and Accountability Act-compliant electronic database.<xref rid="R16" ref-type="bibr">16</xref> For screening purposes, potentially eligible patients are defined as patients ≥28 weeks’ cGA admitted to the NICU on respiratory support &gt;2 L NC. The study team will be notified by an automated email when new patients are screened and added to the REDCap database. Patients undergoing planned intubations who are on ≤2 L NC are also eligible. To identify these patients, teams will be asked to contact study team members for any planned intubations.</p>
              </sec>
              <sec id="s2-5">
                <title>Recruitment</title>
                <p>A member of the study team will approach parents of eligible infants to offer study participation and obtain informed consent via paper consent or electronic consent using REDCap e-consent (<xref rid="SP1" ref-type="supplementary-material">online supplemental appendix 1</xref>). Participants are currently being recruited and enrolled at both sites at time of submission.</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2023-073400.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2023-073400supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-6">
                <title>Randomisation</title>
                <p>The first five patients at each study site will receive apnoeic oxygenation during a run-in phase. This will enable optimisation of site-specific operational procedures and identification of any site-specific barriers to study procedures prior to randomisation phase. Run-in patients will not be included in final analyses.</p>
                <p>All subsequent patients at each site will undergo randomisation during the randomisation phase (<xref rid="F1" ref-type="fig">figure 1</xref>). The study will employ computer-generated permuted block randomisation with unequal blocks of varying size with an allocation ratio of 1:1 within each block. Pre-randomisation stratification is by site. Given the time-critical nature of the intervention, randomisation cards will be kept in sequentially numbered, sealed, opaque envelopes stored in each NICU adjacent to the respiratory therapy equipment. If a consented infant meets all eligibility criteria, the randomisation envelope will be opened immediately prior to intubation.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>General schema of study design. NICU, neonatal intensive care unit; AO, apnoeic oxygenation.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2023-073400f01" position="float"/>
                </fig>
              </sec>
              <sec id="s2-7">
                <title>Blinding</title>
                <p>The study intervention is unblinded. To protect against potential outcome ascertainment bias, the primary outcome of magnitude of desaturation during intubation is performed blinded to intervention arm.</p>
              </sec>
              <sec id="s2-8">
                <title>Intervention</title>
                <p>The decision to intubate is left to the clinical team’s discretion. If the clinical team determines a consented patient requires intubation, the study equipment pole will be brought to the patient’s bedside (<xref rid="F2" ref-type="fig">figure 2</xref>). The study pole includes all study materials: study-specific NC (Hudson RCI, Teleflex, Morrisville, North Carolina, USA), study-specific pulse oximeter (Masimo Rad-G, Masimo Corp, Irvine, California, USA), randomisation envelopes, study video-recording device (GoPro HERO Session, GoPro, San Mateo, California, USA) and trial workflow education. The clinical team will confirm eligibility criteria reviewing both inclusion and exclusion criteria. If the patient does not meet eligibility criteria, the intubation will proceed per standard of care and the patient will not be randomised. If the patient meets eligibility criteria, the clinical team will place the study pole next to the bedside and start the video-recording device, positioning it with a bird’s-eye view of the infant’s bed. The clinical team will then apply the study-specific pulse oximeter probe to any of the patient’s extremities and place the pulse oximeter on the bed in view of the video-recording device. The team will open the randomisation envelope and treatment allocation will be announced at which point the patient is officially enrolled in the trial.</p>
                <fig position="float" id="F2">
                  <label>Figure 2</label>
                  <caption>
                    <p>Study equipment pole.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2023-073400f02" position="float"/>
                </fig>
                <p>Infants randomised to standard of care will receive no additional respiratory support once the facemask is removed from the patient’s face for laryngoscopy and intubation attempt(s). Infants randomised to apnoeic oxygenation will receive 6 L NC 100% oxygen when the facemask is removed from the face for laryngoscopy and intubation attempt(s). Upon completion of the intubation encounter, the NC and the pulse oximeter will be removed, and the video-recording device will be turned off. All subsequent care will follow local unit standard practices and protocols. Co-enrolment in other randomised controlled trials is assessed by the trial coordinating committee on an individual trial basis.</p>
              </sec>
              <sec id="s2-9">
                <title>Primary outcome measure</title>
                <p>The primary outcome is the magnitude of desaturation during the intubation encounter, defined as the change in oxygen saturation from the SpO<sub>2</sub> value at the time of facemask removal prior to the first intubation attempt to the lowest SpO<sub>2</sub> value during any intubation attempt(s) during the encounter (<xref rid="T1" ref-type="table">table 1</xref>). An attempt is defined by placement of the laryngeal blade in the patient’s mouth and the duration of the attempt is defined as time from mask off face to re-initiation of positive pressure ventilation through a correctly placed endotracheal tube, laryngeal mask airway or facemask.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Primary and secondary outcomes</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Primary outcome</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Definition</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Magnitude of oxygen desaturation during the intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Change in oxygen saturation from the SpO<sub>2</sub> value at the time of facemask removal prior to the first intubation attempt to the lowest SpO<sub>2</sub> value during any intubation attempt(s) during the encounter</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" colspan="2" rowspan="1">
                          <bold>Secondary outcomes</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Efficacy</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Definitions</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Severe oxygen desaturation: ≥20% decline in SpO<sub>2</sub></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≥20% decline in SpO<sub>2</sub> from SpO<sub>2</sub> at time of mask off face for first attempt to lowest SpO<sub>2</sub> during any intubation attempt</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">SpO<sub>2</sub> &lt;80% during intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dichotomous variable, did SpO<sub>2</sub> fall &lt;80% at any point during any intubation attempt</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Time to SpO<sub>2</sub> &lt;80% from facemask removal during intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Time in seconds until SpO<sub>2</sub> falls &lt;80% during each attempt</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">First intubation attempt success</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Successfully placed ETT on first time blade is placed in mouth</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of intubation attempts</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of times the mask is removed, and blade is placed in the mouth after which ventilation is resumed. If the blade is placed and removed multiple times without PPV between placements, this is counted as one attempt.</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Duration of each intubation attempt</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Time from mask off face to re-initiation of PPV through correctly placed ETT, LMA or facemask PPV. This definition will be used throughout our primary analysis</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Magnitude of HR decline during intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Change in HR from highest HR immediately prior to first intubation attempt minus lowest HR at any point during any intubation attempt during the encounter</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">First blood gas pH following intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">pH on first blood gas after intubation if completed within 24 hours of intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">First blood gas pCO<sub>2</sub> following intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">pCO<sub>2</sub> on first blood gas after intubation if completed within 24 hours of intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">First blood gas pO<sub>2</sub> following intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">pO<sub>2</sub> on first blood gas after intubation if completed within 24 hours of intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Feasibility</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Definitions</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Apnoeic oxygenation fidelity</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportion of subjects allocated to apnoeic oxygenation who were successfully provided apnoeic oxygenation<break/>Apnoeic oxygenation<break/>Yes: NC placed in nares during each attempt with 6 L/min at 1.0 FiO<sub>2</sub> and not purposefully removed before an attempt was completed<break/>No: NC was not placed during each attempt, NC was purposefully removed before an attempt was completed, flow was &lt;/&gt;6 L or FiO<sub>2</sub> was &lt;100%</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportion of intubated infants who were successfully screened in advance of intubation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of screened neonates who underwent intubation/number of neonates ≥28 weeks’ cGA who underwent intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Informed consent rates</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of patients who are consented divided by number of patients who were approached</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proportion of consented infants who were ultimately randomised</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of patients randomised divided by number of patients consented</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of protocol deviations and violations</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sum of number of protocol violations/deviations</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Safety</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>Definitions</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Cardiopulmonary resuscitation within 1 hour of intubation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Defined as need for chest compressions with or without epinephrine within 1 hour of intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">New pneumothorax within 24 hours of intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Defined as any pneumothorax on radiology read in 24 hours after intubation that was not present prior to intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">New nasal trauma within 24 hours of intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any new nasal trauma within 24 hours of intubation (abrasions, pressure injury or bleeding) that was not previously in place before intubation</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Duration of time with SpO<sub>2</sub>=100% during intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Defined as amount of time in seconds SpO<sub>2</sub>=100% during all intubation attempts during the encounter</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of adverse tracheal intubation-associated events (TIAEs) during the intubation encounter</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number of TIAEs during intubation encounter. Defined per NEAR4NEOS definitions</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>cGA, corrected gestational age; ETT, endotracheal tube; FiO<sub>2</sub>, fraction of inspired oxygen; HR, heart rate; LMA, laryngeal mask airway; NC, nasal cannula; NEAR4NEOS, National Emergency Airway Registry for Neonates; pCO<sub>2</sub>, partial pressure of carbon dioxide; pH, potential of hydrogen; pO<sub>2</sub>, partial pressure of oxygen; PPV, positive pressure ventilation; SpO<sub>2</sub>, pulse oximetry saturation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-10">
                <title>Secondary outcome</title>
                <p>We will capture important secondary outcomes including further efficacy, feasibility and safety outcomes (<xref rid="T1" ref-type="table">table 1</xref>). All primary and secondary outcomes will be ascertained within 24 hours of intubation.</p>
              </sec>
              <sec id="s2-11">
                <title>Sample size</title>
                <p>Using preliminary available data from the study sites, we estimate the mean absolute decline in SpO<sub>2</sub> during tracheal intubations in the control arm will be 26% with an SD of 25%. To have 80% power to detect an effect size of 0.54 (or 13.5% difference in mean decline of SpO<sub>2</sub>) with an alpha of 0.05, we will need 110 randomised infants (<xref rid="T2" ref-type="table">table 2</xref>). The effect size is the (absolute) difference in mean decline in SpO<sub>2</sub> between the two arms divided by the SD of declines: 13.5÷25=0.54. We will enrol 120 infants, 10 in the run-in phase and 110 in the randomisation phase.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Sample size calculation</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Power</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">N1</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">N2</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">N</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Effect size</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Alpha</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">100</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.57</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.80</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>55</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>55</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>110</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.54</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.05</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">60</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">60</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">120</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.52</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">130</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2_FN1">
                      <p>The detectable effect size based on application of a two-sided two-sample t-test with common SD, assuming group sizes N1 and N2 (N=N1+N2) and type-one error (alpha) of 0.05.</p>
                    </fn>
                    <fn id="T2_FN2">
                      <p>The bolded row represents the selected sample size.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-12">
                <title>Data collection</title>
                <p>Data will be collected from four sources: the study-specific pulse oximeter, the video-recording device, the EMR and the National Emergency Airway Registry for Neonates (NEAR4NEOS). NEAR4NEOS is an international multicentre airway registry which captures tracheal intubation process and outcome measures.<xref rid="R1" ref-type="bibr">1</xref> After a patient is randomised, a team member will download the pulse oximeter data and the video of the intubation. An unblinded team member will review the video for protocol adherence and intubation time stamps. A team member blinded to intervention arm will then review the downloaded pulse oximeter data with the intubation time stamps to calculate primary and secondary physiological outcomes. An unblinded team member will extract the remaining secondary outcomes from the EMR and NEAR4NEOS data.</p>
              </sec>
              <sec id="s2-13">
                <title>Statistical analysis</title>
                <p>All statistical analyses will be conducted using Stata V.17 (Stata Corp, College Station, Texas, USA). An intention-to-treat analysis will estimate whether apnoeic oxygenation is superior to standard of care in reducing the magnitude of oxygen desaturation. The analyses will be performed according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting parallel group randomised trials.<xref rid="R17" ref-type="bibr">17</xref> The primary and secondary outcomes (<xref rid="T1" ref-type="table">table 1</xref>) recorded for eligible infants enrolled in the randomisation phase will be evaluated via intention-to-treat statistical analysis. The effect sizes for primary and secondary outcomes will be estimated, with 95% CIs as a measure of precision of estimation. The analysis of the primary outcome will be conducted using linear regression to control for residual confounding by clinical site, as the randomisation will be stratified on this variable, consistent with the CONSORT statement.</p>
                <p>We will also conduct exploratory and hypothesis-generating secondary analyses of the primary outcome for this trial. In these analyses, we will adjust for potentially important prognostic covariates, including patient weight at intubation, patient biological sex, respiratory support prior to intubation (as a proxy for baseline lung disease), use of video laryngoscope and first provider intubation competence. We will employ a manual stepwise approach that first fits a model that includes all variables and will then remove the variable with the largest p value, until all p values are &lt;0.05. We will report results from these secondary analyses but will consider the results from the analysis adjusted for site only to be primary.</p>
                <p>We will perform two subgroup analyses to explore the influence of first provider intubation competence and patients’ baseline lung disease. We will use cumulative summation methodology to define providers as procedurally competent, deficient or undifferentiated at time of each intubation, based on their past intubation performance.<xref rid="R18" ref-type="bibr">18</xref> We will use patients’ level of respiratory support prior to intubation as a proxy for baseline lung disease dichotomising this variable into low support (≤5 L high-flow NC) and high support (&gt;5 L high-flow NC).</p>
                <p>Secondary outcomes will be analysed using similar procedures to the primary outcome. Comparisons between treatment arms will use logistic regression, linear regression or time-to-event analyses, as appropriate.</p>
                <p>We do not anticipate significant loss to follow-up for the primary endpoint given the proximity to randomisation. However, missing data from the pulse oximeter are possible. We will therefore perform two sensitivity analyses using physiological data reported for the encounter in NEAR4NEOS to assess oxygen desaturation defined in two ways: severe oxygen desaturation (≥20% decline in SpO<sub>2</sub>) and desaturation &lt;80% during intubation encounter. The protocol (<xref rid="SP2" ref-type="supplementary-material">online supplemental appendix 2</xref>) and the statistical analysis plan (<xref rid="SP3" ref-type="supplementary-material">online supplemental appendix 3</xref>) describe further details of statistical analyses.</p>
                <supplementary-material id="SP2" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2023-073400.supp2</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS2" xlink:href="bmjopen-2023-073400supp002.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <supplementary-material id="SP3" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2023-073400.supp3</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS3" xlink:href="bmjopen-2023-073400supp003.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-14">
                <title>Trial organisation plan</title>
                <p>Trial supervision will consist of a Clinical Coordination Committee, a Data Coordination Committee, a Steering Committee (SC) and a Data Safety Monitoring Board (DSMB). Composition, roles and responsibilities are described in <xref rid="SP4" ref-type="supplementary-material">online supplemental appendix 4</xref>.</p>
                <supplementary-material id="SP4" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2023-073400.supp4</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS4" xlink:href="bmjopen-2023-073400supp004.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-15">
                <title>Safety</title>
                <p>A DSMB will monitor the safety of all infants involved in the study and ensure the validity and integrity of the data. The three-member committee will be independent of the study investigators and sponsors and without competing interests. For this pilot trial, the primary responsibility of the DSMB will be to ensure the safety of study participants. To meet this responsibility, the DSMB will familiarise themselves with the research protocol and consent forms. They will review interim reports of adverse incidents, interim reports of trial participant accrual and feasibility outcomes, and reports from related studies to determine whether those results indicate the need to change or terminate the present trial. They will make recommendations to the investigators concerning continuation, termination or modification of the trial. The SC will prepare the interim reports issued to the DSMB.</p>
              </sec>
              <sec id="s2-16">
                <title>Interim analyses</title>
                <p>There will be two safety reviews performed by the DSMB throughout the study. The DSMB will review specified safety events to ensure the study does not impose undue extra risk on infants undergoing tracheal intubation.</p>
              </sec>
              <sec id="s2-17">
                <title>Harms</title>
                <p>Unanticipated problems related to the research involving risks to subjects or others that occur during this study (including serious adverse events) will be reported to the Institutional Review Board (IRB) in accordance with IRB policy. Adverse events that are not serious but that are notable and could involve risks to subjects will be summarised and submitted to the IRB at the time of continuing review.</p>
                <p>All adverse events will be noted in the study records with a full description including the nature, date and time of onset, determination of non-serious versus serious, intensity (mild, moderate, severe), duration, causality and outcome of the event.</p>
              </sec>
              <sec id="s2-18">
                <title>Duration of study</title>
                <p>Study recruitment started in July 2022. The anticipated end date would be on 31 January 2024.</p>
              </sec>
              <sec id="s2-19">
                <title>Quality control and quality assurance procedures</title>
                <p>The study team conducted extensive education and training with all disciplines involved in intubation at each site to ensure protocol understanding and compliance prior to study initiation. The team developed a training video demonstrating both arms of the intervention to augment the educational curriculum. Additionally, the protocol includes a run-in phase where the first five patients at each site receive apnoeic oxygenation to establish site-specific operational procedures and to identify any site-specific barriers to study procedures. During the study period, weekly email reminders with refresher education will be sent to clinical teams with consented patients. Lastly, all trial intubations will be video recorded to assess protocol adherence and address quality control issues.</p>
              </sec>
              <sec id="s2-20">
                <title>Data processing, monitoring and security</title>
                <p>Data will primarily be managed using REDCap electronic data capture tools at the Children’s Hospital of Philadelphia and the University of Pennsylvania.<xref rid="R16" ref-type="bibr">16</xref> A manual of operations will serve as a reference guide for study procedures, data dictionaries, data collection, data handling and reporting. Access to patient direct identifiers will be limited to study staff with required training and who must access identifiers for study-specific procedures. All identifiable data will be stored on firewall-protected secure servers.</p>
              </sec>
              <sec id="s2-21">
                <title>Patient and public involvement</title>
                <p>Patients and public were not involved in the development of this protocol, choice of outcomes or study recruitment. The parents of patients will be informed of the plan to publish results during the informed consent process.</p>
              </sec>
            </sec>
            <sec id="s3">
              <title>Ethics and dissemination</title>
              <sec id="s3-1">
                <title>Ethics</title>
                <p>The study was approved by the IRB at the Children’s Hospital of Philadelphia and the University of Pennsylvania at the time of this submission.</p>
              </sec>
              <sec id="s3-2">
                <title>Protocol amendments</title>
                <p>Current protocol version is 5.3 at time of submission; most revisions pertained to study staff changes or clarification of exclusion criteria. All protocol amendments will be submitted to the IRB and recorded in a protocol change log. Protocol amendments will be disseminated to investigators and study team members. Any amendments that directly affect trial participants or change the risk profile of the trial will be communicated directly to trial participants. The protocol change log will be submitted with the manuscript at time of publication.</p>
              </sec>
              <sec id="s3-3">
                <title>Dissemination</title>
                <p>Upon trial completion, we intend to submit results of our primary analyses to the peer review forum. Our broader dissemination goals include a timely peer-reviewed submission targeting a paediatric journal. We will adhere to standard authorship eligibility guidelines.</p>
              </sec>
              <sec id="s3-4">
                <title>Data access</title>
                <p>The principal investigator will make data available after study completion in accordance with National Institutes of Health policies. Our data will only be provided to those investigators who agree to adhere to a signed research data use agreement. The execution of the agreement will require IRB approval or demonstration of IRB exemption per institutional policy.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e235">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2023-073400.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e236">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2023-073400.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> HMH contributed to design of the project, drafted the initial manuscript, critically reviewed and revised the manuscript, and approved the final manuscript. MO'R, SL, PW, NN and JS contributed to design of the project, critically reviewed and revised the manuscript, and approved the final manuscript. AN and EEF conceptualised and designed the study, critically reviewed and revised the manuscript, and approved the final manuscript.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This work was supported by the NIH grant number R21HD103927. HMH is supported by an AHRQ career development award (K08HS029029).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Disclaimer:</bold> The funder had no role in the study design, collection, management, analysis or interpretation of data, nor decision to submit for publication.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; peer reviewed for ethical and funding approval prior to submission.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not required.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foglia</surname><given-names>EE</given-names></string-name>, <string-name><surname>Ades</surname><given-names>A</given-names></string-name>, <string-name><surname>Sawyer</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neonatal intubation practice and outcomes: an international registry study</article-title>. <source>Pediatrics</source><year>2019</year>;<volume>143</volume>:<elocation-id>e20180902</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2018-0902</pub-id><pub-id pub-id-type="pmid">30538147</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Fiore</surname><given-names>JM</given-names></string-name>, <string-name><surname>Poets</surname><given-names>CF</given-names></string-name>, <string-name><surname>Gauda</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cardiorespiratory events in preterm infants: interventions and consequences</article-title>. <source>J Perinatol</source><year>2016</year>;<volume>36</volume>:<fpage>251</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/jp.2015.165</pub-id><pub-id pub-id-type="pmid">26583943</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poets</surname><given-names>CF</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>RS</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants</article-title>. <source>JAMA</source><year>2015</year>;<volume>314</volume>:<fpage>595</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.8841</pub-id><pub-id pub-id-type="pmid">26262797</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Fiore</surname><given-names>JM</given-names></string-name>, <string-name><surname>Bloom</surname><given-names>JN</given-names></string-name>, <string-name><surname>Orge</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity</article-title>. <source>J Pediatr</source><year>2010</year>;<volume>157</volume>:<fpage>69</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2010.01.046</pub-id><pub-id pub-id-type="pmid">20304417</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name><surname>Denson</surname><given-names>SE</given-names></string-name>, <string-name><surname>Mancuso</surname><given-names>TJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Premedication for nonemergency endotracheal intubation in the neonate</article-title>. <source>Pediatrics</source><year>2010</year>;<volume>125</volume>:<fpage>608</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2009-2863</pub-id><pub-id pub-id-type="pmid">20176672</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grude</surname><given-names>O</given-names></string-name>, <string-name><surname>Solli</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of nasal or nasopharyngeal apneic oxygenation on desaturation during induction of anesthesia and endotracheal intubation in the operating room: a narrative review of randomized controlled trials</article-title>. <source>J Clin Anesth</source><year>2018</year>;<volume>51</volume>:<fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinane.2018.07.002</pub-id><pub-id pub-id-type="pmid">30029021</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steiner</surname><given-names>JW</given-names></string-name>, <string-name><surname>Sessler</surname><given-names>DI</given-names></string-name>, <string-name><surname>Makarova</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Use of deep laryngeal oxygen insufflation during laryngoscopy in children: a randomized clinical trial</article-title>. <source>Br J Anaesth</source><year>2016</year>;<volume>117</volume>:<fpage>350</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/bja/aew186</pub-id><pub-id pub-id-type="pmid">27466252</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Windpassinger</surname><given-names>M</given-names></string-name>, <string-name><surname>Plattner</surname><given-names>O</given-names></string-name>, <string-name><surname>Gemeiner</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pharyngeal oxygen insufflation during airtraq laryngoscopy slows arterial desaturation in infants and small children</article-title>. <source>Anesth Analg</source><year>2016</year>;<volume>122</volume>:<fpage>1153</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0000000000001189</pub-id><pub-id pub-id-type="pmid">26991620</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humphreys</surname><given-names>S</given-names></string-name>, <string-name><surname>Lee-Archer</surname><given-names>P</given-names></string-name>, <string-name><surname>Reyne</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Transnasal humidified rapid-insufflation ventilatory exchange (thrive) in children: a randomized controlled trial</article-title>. <source>Br J Anaesth</source><year>2017</year>;<volume>118</volume>:<fpage>232</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/bja/aew401</pub-id><pub-id pub-id-type="pmid">28100527</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Napolitano</surname><given-names>N</given-names></string-name>, <string-name><surname>Laverriere</surname><given-names>EK</given-names></string-name>, <string-name><surname>Craig</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apneic oxygenation as a quality improvement intervention in an academic PICU</article-title>. <source>Pediatric Critical Care Medicine</source><year>2019</year>;<volume>20</volume>:<fpage>1</fpage>. <pub-id pub-id-type="doi">10.1097/PCC.0000000000002123</pub-id><pub-id pub-id-type="pmid">30407953</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname><given-names>E</given-names></string-name>, <string-name><surname>Cincotta</surname><given-names>DR</given-names></string-name>, <string-name><surname>Grindlay</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A quality improvement initiative to increase the safety of pediatric emergency airway management</article-title>. <source>Paediatr Anaesth</source><year>2017</year>;<volume>27</volume>:<fpage>1271</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/pan.13275</pub-id><pub-id pub-id-type="pmid">29063722</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vukovic</surname><given-names>AA</given-names></string-name>, <string-name><surname>Hanson</surname><given-names>HR</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apneic oxygenation reduces hypoxemia during endotracheal intubation in the pediatric emergency department</article-title>. <source>Am J Emerg Med</source><year>2019</year>;<volume>37</volume>:<fpage>27</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2018.04.039</pub-id><pub-id pub-id-type="pmid">29699900</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Napolitano</surname><given-names>N</given-names></string-name>, <string-name><surname>Polikoff</surname><given-names>L</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of apneic oxygenation with intubation to reduce severe desaturation and adverse tracheal intubation-associated events in critically ill children</article-title>. <source>Crit Care</source><year>2023</year>;<volume>27</volume>:<elocation-id>26</elocation-id>. <pub-id pub-id-type="doi">10.1186/s13054-023-04304-0</pub-id><pub-id pub-id-type="pmid">36650568</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foran</surname><given-names>J</given-names></string-name>, <string-name><surname>Moore</surname><given-names>CM</given-names></string-name>, <string-name><surname>Ni Chathasaigh</surname><given-names>CM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Nasal high-flow therapy to optimise stability during intubation: the NOSI pilot trial</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source><year>2022</year>:<elocation-id>fetalneonatal-2022-324649</elocation-id>. <pub-id pub-id-type="doi">10.1136/archdischild-2022-324649</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hodgson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Owen</surname><given-names>LS</given-names></string-name>, <string-name><surname>Kamlin</surname><given-names>COF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Nasal high-flow therapy during neonatal endotracheal intubation</article-title>. <source>N Engl J Med</source><year>2022</year>;<volume>386</volume>:<fpage>1627</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2116735</pub-id><pub-id pub-id-type="pmid">35476651</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname><given-names>PA</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R</given-names></string-name>, <string-name><surname>Thielke</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Research electronic data capture (redcap) -- a metadata-driven methodology and workflow process for providing translational research informatics support</article-title>. <source>J Biomed Inform</source><year>2009</year>;<volume>42</volume>:<fpage>377</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id><pub-id pub-id-type="pmid">18929686</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name></person-group>. <article-title>Consort 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>J Pharmacol Pharmacother</source><year>2010</year>;<volume>1</volume>:<fpage>100</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4103/0976-500X.72352</pub-id><pub-id pub-id-type="pmid">21350618</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evans</surname><given-names>P</given-names></string-name>, <string-name><surname>Shults</surname><given-names>J</given-names></string-name>, <string-name><surname>Weinberg</surname><given-names>DD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Intubation competence during neonatal fellowship training</article-title>. <source>Pediatrics</source><year>2021</year>;<volume>148</volume>:<elocation-id>e2020036145</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2020-036145</pub-id><pub-id pub-id-type="pmid">34172556</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
